Literature DB >> 32428928

Mesocortical BDNF signaling mediates antidepressive-like effects of lithium.

Di Liu1,2, Qian-Qian Tang1,2, Di Wang1,2, Su-Pei Song1,2, Xiao-Na Yang1,2, Su-Wan Hu1,2, Zhi-Yong Wang1,2, Zheng Xu1,2, He Liu1,2, Jun-Xia Yang1,2, Sarah E Montgomery3,4, Hongxing Zhang1,2, Ming-Hu Han3,4, Hai-Lei Ding5,6, Jun-Li Cao7,8,9.   

Abstract

Lithium has been used to treat major depressive disorder, yet the neural circuit mechanisms underlying this therapeutic effect remain unknown. Here, we demonstrated that the ventral tegmental area (VTA) dopamine (DA) neurons that project to the medial prefrontal cortex (mPFC), but not to nucleus accumbens (NAc), contributed to the antidepressive-like effects of lithium. Projection-specific electrophysiological recordings revealed that high concentrations of lithium increased firing rates in mPFC-, but not NAc-, projecting VTA DA neurons in mice treated with chronic unpredictable mild stress (CMS). In parallel, chronic administration of high-dose lithium in CMS mice restored the firing properties of mPFC-projecting DA neurons, and also rescued CMS-induced depressive-like behaviors. Nevertheless, chronic lithium treatment was insufficient to change the basal firing rates in NAc-projecting VTA DA neurons. Furthermore, chemogenetic activation of mPFC-, but not NAc-, projecting VTA DA neurons mimicked the antidepressive-like effects of lithium in CMS mice. Chemogenetic downregulation of VTA-mPFC DA neurons' firing activity abolished the antidepressive-like effects of lithium in CMS mice. Finally, we found that the antidepressant-like effects induced by high-dose lithium were mediated by BNDF signaling in the mesocortical DA circuit. Together, these results demonstrated the role of mesocortical DA projection in antidepressive-like effects of lithium and established a circuit foundation for lithium-based antidepressive treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32428928      PMCID: PMC7360776          DOI: 10.1038/s41386-020-0713-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  77 in total

Review 1.  Lithium: clinical considerations in internal medicine.

Authors:  Marlene P Freeman; Scott A Freeman
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

Review 2.  Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.

Authors:  Todd D Gould; Husseini K Manji
Journal:  Neuropsychopharmacology       Date:  2005-07       Impact factor: 7.853

Review 3.  A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.

Authors:  J Craig Nelson; Pierre Baumann; Kevin Delucchi; Russell Joffe; Cornelius Katona
Journal:  J Affect Disord       Date:  2014-06-02       Impact factor: 4.839

4.  Lithium for long-term treatment of unipolar depression.

Authors:  Allan H Young
Journal:  Lancet Psychiatry       Date:  2017-06-01       Impact factor: 27.083

Review 5.  Evidence-based pharmacotherapy of treatment-resistant unipolar depression.

Authors:  Markus Dold; Siegfried Kasper
Journal:  Int J Psychiatry Clin Pract       Date:  2016-11-16       Impact factor: 1.812

Review 6.  Lithium in the treatment of mood disorders.

Authors:  L H Price; G R Heninger
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

7.  Lithium treatment for unipolar major depressive disorder: Systematic review.

Authors:  Juan Undurraga; Kang Sim; Leonardo Tondo; Ariel Gorodischer; Emilio Azua; Kai Hong Tay; David Tan; Ross J Baldessarini
Journal:  J Psychopharmacol       Date:  2019-01-30       Impact factor: 4.153

Review 8.  Chronic and treatment resistant depression: diagnosis and stepwise therapy.

Authors:  Tom Bschor; Michael Bauer; Mazda Adli
Journal:  Dtsch Arztebl Int       Date:  2014-11-07       Impact factor: 5.594

Review 9.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models.

Authors:  Fiona Kerr; Ivana Bjedov; Oyinkan Sofola-Adesakin
Journal:  Front Mol Neurosci       Date:  2018-08-28       Impact factor: 5.639

View more
  2 in total

1.  lncRNA MIR155HG Alleviates Depression-Like Behaviors in Mice by Regulating the miR-155/BDNF Axis.

Authors:  Zhang Huan; Zhu Mei; Huang Na; Ma Xinxin; Wang Yaping; Liu Ling; Wang Lei; Zhang Kejin; Liu Yanan
Journal:  Neurochem Res       Date:  2021-01-29       Impact factor: 3.996

2.  Lithium therapy subdues neuroinflammation to maintain pyramidal cells arborization and rescues neurobehavioural impairments in ovariectomized rats.

Authors:  Anil Kumar Rana; Supriya Sharma; Vikram Patial; Damanpreet Singh
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.